Figure 6. Improving ACT effectiveness by favoring intra-tumoral myeloid balance towards Tip-DC accumulation.

(A) EG7 tumor-bearing WT mice were treated with either anti-CSF-1R or Ctrl antibody, followed or not by ACT with OVA-specific CD8⁺CD45.1⁺ T lymphocytes. Percent of different myeloid subpopulations in CD11b⁺NOS2⁺ gate within the tumor mass is shown. n=12, pooled from 2 independent experiments.

(B–C) WT (B) or NOS KO (C) MCA203 tumor-bearing mice were treated weekly with either anti-CSF-1R or Ctrl antibody and injected or not with mTERT-specific CD8⁺ T lymphocytes. Tumor volume at indicated days is shown as mean ± s.d., (n=15).

(D) Percent of different immune subpopulations in tumors from mice treated with anti-CSF-1R or Ctrl antibody with or without ACT, (n=8).

(A, D) Error bars indicate mean ± s.d., ***p ≤ 0.001, **p ≤ 0.01 and *p ≤ 0.05, by using One Way ANOVA.

See also figure S6.